Clinical Application of Pharmacogenomics
Authors:
- 11 June 2012
- journal article
- research article
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 25 (4) , 417-427
Abstract
The purpose of this review is to discuss the clinical application of pharmacogenomics for select drug therapies (eg, proton pump inhibitors [PPIs], codeine, and carbamazepine) and to highlight limitations and challenges that preclude implementation of pharmacogenomics into clinical practice. Genetic polymorphisms of cytochrome P450 (CYP) enzymes and the presence of the human leukocyte antigen (HLA)-B*1502 allele influence drug disposition and/or response. A portion of PPI pharmacokinetic and pharmacodynamic variability can be explained by CYP2C19 genotype. However, conflicting evidence exists related to Helicobacter pylori cure rates based on CYP2C19 genotype. For codeine, adverse drug reactions in neonates through breast-feeding from CYP2D6 ultra-rapid metabolizers have been reported. However, there is lack of conclusive evidence regarding the overall influence of CYP2D6 polymorphisms on codeine efficacy and toxicity. Although CYP2C19 and CYP2D6 genotyping tests are available, clinical utility remains low. The presence of the HLA-B*1502 allele is associated with carbamazepine-induced Stevens-Johnson syndrome (SJS) and/or toxic epidermal necrolysis (TEN). Pharmacogenomic testing is required prior to initiating carbamazepine in high-risk patients. Lack of sufficient resources, provider knowledge, and ethical, legal, and social issues are several limitations and challenges to implementing pharmacogenomic testing in clinical practice.Keywords
This publication has 103 references indexed in Scilit:
- Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary interventionVascular Health and Risk Management, 2011
- HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in EuropeansNew England Journal of Medicine, 2011
- Drug-Drug Interaction Profiles of Proton Pump InhibitorsClinical Pharmacokinetics, 2010
- The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodoneBritish Journal of Pharmacology, 2010
- Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteersBritish Journal of Clinical Pharmacology, 2008
- Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactionsPharmacogenetics and Genomics, 2006
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClinical Pharmacology & Therapeutics, 2006
- Clinical Significance of the Cytochrome P450 2C19 Genetic PolymorphismClinical Pharmacokinetics, 2002
- Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish populationClinical Pharmacology & Therapeutics, 1999
- Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)Biochemical and Biophysical Research Communications, 1988